Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes
| Autor: | Ian T. Logan, Elizabeth L. Kulakov, C. M. Perrett |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Imiquimod 5% cream
Adult Male medicine.medical_specialty Skin Neoplasms Esthetics medicine.medical_treatment Skin Cream Imiquimod Photodynamic therapy Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Methyl aminolevulinate Antineoplastic Combined Chemotherapy Protocols Medicine Humans Aged Retrospective Studies Aged 80 and over Photosensitizing Agents Index Lesion business.industry Retrospective cohort study General Medicine Aminolevulinic Acid Middle Aged Sequential treatment Combined Modality Therapy Treatment Outcome Tolerability Photochemotherapy Carcinoma Basal Cell 030220 oncology & carcinogenesis Surgery Female Neoplasm Recurrence Local business medicine.drug Follow-Up Studies |
| Zdroj: | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 46(10) |
| ISSN: | 1524-4725 |
| Popis: | BACKGROUND Topical photodynamic therapy (PDT) and imiquimod 5% (IMQ) cream are established treatments for superficial basal cell carcinoma (sBCC). Both have high initial response rates and recurrence rates of up to 37%. Recent studies demonstrate that PDT and imiquimod may act on sBCCs via synergistic immunomodulatory pathways. OBJECTIVE To describe the sequential use of MAL-PDT and imiquimod 5% cream in the treatment of sBCCs and report treatment tolerability, cosmetic outcomes, and efficacy. MATERIALS AND METHODS This is a retrospective case series of patients presenting over a 2-year period with primary sBCC who underwent 2 cycles of topical MAL-PDT, followed by 6 weeks of imiquimod 5% cream. Outcome measures were resolution of the index lesion at 3 months, side effects, cosmetic outcome, and long-term recurrence (LTR). RESULTS A total of 17 consecutive patients (n = 17) with a combined 21 sBCCs (n = 21) were included. The median length of follow-up was 72 months (range 24-95 months). Long-term recurrence occurred in 2/21 lesions (10%). CONCLUSION Sequential use of PDT and imiquimod was well tolerated with good cosmetic outcomes. The 10% LTR rate is at the lower end of the range reported for single modality treatment; however, larger samples are required to evaluate efficacy differences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|